MA43871A - Inhibition du lymphome 2 à cellules b (bcl -2) et des protéines apparentées - Google Patents

Inhibition du lymphome 2 à cellules b (bcl -2) et des protéines apparentées

Info

Publication number
MA43871A
MA43871A MA043871A MA43871A MA43871A MA 43871 A MA43871 A MA 43871A MA 043871 A MA043871 A MA 043871A MA 43871 A MA43871 A MA 43871A MA 43871 A MA43871 A MA 43871A
Authority
MA
Morocco
Prior art keywords
bcl
inhibition
cell lymphoma
related proteins
proteins
Prior art date
Application number
MA043871A
Other languages
English (en)
Inventor
Daryl C Drummond
Bolin Geng
Dmitri B Kirpotin
Alexander Koshkaryev
Suresh K Tipparaju
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of MA43871A publication Critical patent/MA43871A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA043871A 2016-01-11 2017-01-11 Inhibition du lymphome 2 à cellules b (bcl -2) et des protéines apparentées MA43871A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662277248P 2016-01-11 2016-01-11
US201762444168P 2017-01-09 2017-01-09

Publications (1)

Publication Number Publication Date
MA43871A true MA43871A (fr) 2018-11-21

Family

ID=59312078

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043871A MA43871A (fr) 2016-01-11 2017-01-11 Inhibition du lymphome 2 à cellules b (bcl -2) et des protéines apparentées

Country Status (5)

Country Link
EP (1) EP3402485A1 (fr)
JP (1) JP2019501225A (fr)
AU (1) AU2017206731A1 (fr)
MA (1) MA43871A (fr)
WO (1) WO2017123616A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL316472A (en) 2018-01-10 2024-12-01 Recurium Ip Holdings Llc Benzamide compounds
CN112996854B (zh) 2018-09-19 2024-08-30 摩登纳特斯有限公司 高纯度peg脂质和其用途
CN110143941B (zh) * 2019-06-04 2021-05-25 北京四环制药有限公司 一种巴罗萨韦玛波酯中间体的合成方法
EP3972601A4 (fr) * 2019-07-10 2023-07-12 Recurium IP Holdings, LLC Formulation de nanoparticules d'inhibiteur de la bcl-2
CN114786654A (zh) * 2019-12-11 2022-07-22 密执安大学评议会 用于全身递送Bcl-2和Bcl-xL拮抗剂的组合物和方法
CA3175913A1 (fr) * 2021-07-16 2023-01-16 Celator Pharmaceuticals, Inc. Formulations de liposome d'inhibiteurs de bcl
US20250177302A1 (en) * 2022-03-31 2025-06-05 Eisai R&D Management Co., Ltd. Liposome composition and liposome-containing pharmaceutical composition
WO2024012557A1 (fr) * 2022-07-15 2024-01-18 Berrybio (Hong Kong) Limited Agents de dégradation de protéines anti-apoptotiques de la famille bcl-2, compositions pharmaceutiques et applications thérapeutiques
WO2025019346A2 (fr) * 2023-07-14 2025-01-23 Celator Pharmaceuticals, Inc. Méthodes d'utilisation d'une composition liposomale comprenant un inhibiteur d'atr

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5043164A (en) * 1989-01-17 1991-08-27 The University Of Tennessee Research Corporation Blood-stable, cholesterol-free liposomes
KR101462825B1 (ko) * 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
ES2493466T3 (es) * 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
MX2009002422A (es) * 2006-09-05 2009-03-20 Abbott Lab Inhibidores bcl para tratar exceso de plaquetas.
BR112012005343A2 (pt) * 2009-09-10 2016-03-22 Novartis Ag sulfonamidas como inibidores de proteínas da família bcl-2 para o tratamento de câncer

Also Published As

Publication number Publication date
WO2017123616A1 (fr) 2017-07-20
EP3402485A1 (fr) 2018-11-21
JP2019501225A (ja) 2019-01-17
AU2017206731A1 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
EP4003319A4 (fr) Inhibiteurs de hdac6 et leurs utilisations
EP3836561C0 (fr) Unité haut-parleur et dispositif haut-parleur
LT3788042T (lt) Bcl-2 inhibitoriai
MA50860A (fr) Récepterus chimériques d'antigène contre l'antigène de maturation des cellules b et polynucleotides codants
IL271275A (en) Compositions comprising curons and uses thereof
IL282090A (en) Tyk2 inhibitors and uses thereof
DK3697405T3 (da) Ny mek-inhibitor til behandlingen af virale og bakterielle infektioner
PL3694529T3 (pl) Trójswoiste białka i sposoby zastosowania
EP3645739A4 (fr) Procédés et compositions pour le traitement du mélanome
EP3377042A4 (fr) Substances et procédés de traitement de myopathies à base de titine et d'autres titinopathies
DK3578547T3 (da) Sulfonylureaer og relaterede forbindelser og brug af samme
MA45270A (fr) Compositions d'oligonucléotides et procédés associés
MA42819A (fr) Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae
IL280655A (en) Particles containing coloring agents and methods of using the same
DK3595653T3 (da) Sammensætninger af plinabulin og anvendelse heraf
IL283782A (en) Anellosomes and methods of use
HUE052468T2 (hu) Arginázgátlók és terápiás alkalmazásaik
EP3666729A4 (fr) Composition contenant du nano-soufre et application associée
EP3525855A4 (fr) Inhalateur et procédés d'utilisation associés
EP3635000A4 (fr) Manabodies et procédés d'utilisation
IL291217A (en) Usp30 inhibitors and uses thereof
EP3442505A4 (fr) Associations pour le traitement de néoplasmes à l'aide du ciblage de cellules inactives et d'inhibiteurs de l'egfr
EP3849664C0 (fr) Composés phénoxy-pyridyl-pyrimidine et méthodes d'utilisation associées
EP3706947A4 (fr) Étalonnage d'entrelacement et procédés d'utilisation de celui-ci
IL291192A (en) Compositions and methods of treating lupus nephritis